SCHEMBL6841882

SCHEMBL6841882

COc1ccc(CCCCOC(=O)c2ccc3c(c2)C(Cl)(Cl)c2cc(C(=O)OCCCCc4ccc(OC)cc4)ccc2-3)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
CYP3A4 P08684 2/20 0.44
CHRM1 P11229 2/20 0.44
ADRB2 P07550 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
CYP2D6 P10635 1/20 0.44
DRD2 P14416 1/20 0.44
TSHR P16473 1/20 0.44
ADRA2B P18089 1/20 0.44
ADRA2C P18825 1/20 0.44
CHRM3 P20309 1/20 0.44
SLC6A2 P23975 1/20 0.44
HTR2A P28223 1/20 0.44
SLC6A4 P31645 1/20 0.44
DRD3 P35462 1/20 0.44
OPRK1 P41145 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6836982 0.82 ESR1 (0.48) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL6836839 0.77 ESR1 (0.57) MAPTNPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL27915221 0.75 NPC1 (0.60) MAPTNPC1RAB9ASMN1; SMN2CHRM1
SCHEMBL27824110 0.74 SMN1; SMN2 (0.64) MAPTNPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL18660635 0.73 NPC1 (0.88) MAPTNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL13256587 0.72 SMN1; SMN2 (0.62) MAPTNPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL4736573 0.72 ESR1 (0.62) MAPTNPC1RAB9ASMN1; SMN2IGF1R
SCHEMBL15809483 0.72 CALM1 (0.54) MAPTNPC1RAB9ASMN1; SMN2NAAA
SCHEMBL13373945 0.71 NPC1 (0.61) MAPTNPC1RAB9ASMN1; SMN2CYP3A4
SCHEMBL14984033 0.71 NPC1 (0.61) MAPTNPC1RAB9ASMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063785-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use GUILFORD PHARMACEUTICALS, INC. 2004-04-01 US disclosed
US-6635786-B2 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use GUILFORD PHARMACEUTICALS, INC. 2003-10-21 US disclosed
US-20020132852-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use GUILFORD PHARMACEUTICALS, INC. 2002-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063785-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use PARG, PARP1, PARP11 MAPT 1519/4885NPC1 969/4885RAB9A 2581/4885
US-20020132852-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use PARG, PARP1, PARP11 MAPT 1519/4885NPC1 969/4885RAB9A 2581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.